Abstract
Vulvitis circumscripta plasmacellularis (VCP) is a rare but well-described entity. It is notorious for its recalcitrant nature to various modalities of treatment. Intralesional interferon-α showed some promise, with complete resolution, but is coupled with the side-effect of myelosuppression. Topical imiquimod is a novel immune response modifier with the ability to induce the production of interferon-α. In this paper, we report two cases of VCP whose lesions were resistant to antibiotics, topical and oral corticosteroids, but resolved after a treatment trial with imiquimod.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 638-641 |
| Number of pages | 4 |
| Journal | British Journal of Dermatology |
| Volume | 149 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 1 2003 |
| Externally published | Yes |
Fingerprint
Keywords
- Imiquimod
- Vulvitis circumscripta plasmacellularis
- Zoon's vulvitis
ASJC Scopus subject areas
- Dermatology
Cite this
Resolution of vulvitis circumscripta plasmacellularis with topical imiquimod : Two case reports. / Ee, H. L.; Yosipovitch, Gil; Chan, R.; Ong, B. H.; Ee, Melvin.
In: British Journal of Dermatology, Vol. 149, No. 3, 01.09.2003, p. 638-641.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Resolution of vulvitis circumscripta plasmacellularis with topical imiquimod
T2 - Two case reports
AU - Ee, H. L.
AU - Yosipovitch, Gil
AU - Chan, R.
AU - Ong, B. H.
AU - Ee, Melvin
PY - 2003/9/1
Y1 - 2003/9/1
N2 - Vulvitis circumscripta plasmacellularis (VCP) is a rare but well-described entity. It is notorious for its recalcitrant nature to various modalities of treatment. Intralesional interferon-α showed some promise, with complete resolution, but is coupled with the side-effect of myelosuppression. Topical imiquimod is a novel immune response modifier with the ability to induce the production of interferon-α. In this paper, we report two cases of VCP whose lesions were resistant to antibiotics, topical and oral corticosteroids, but resolved after a treatment trial with imiquimod.
AB - Vulvitis circumscripta plasmacellularis (VCP) is a rare but well-described entity. It is notorious for its recalcitrant nature to various modalities of treatment. Intralesional interferon-α showed some promise, with complete resolution, but is coupled with the side-effect of myelosuppression. Topical imiquimod is a novel immune response modifier with the ability to induce the production of interferon-α. In this paper, we report two cases of VCP whose lesions were resistant to antibiotics, topical and oral corticosteroids, but resolved after a treatment trial with imiquimod.
KW - Imiquimod
KW - Vulvitis circumscripta plasmacellularis
KW - Zoon's vulvitis
UR - http://www.scopus.com/inward/record.url?scp=0142120504&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0142120504&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2133.2003.05583.x
DO - 10.1046/j.1365-2133.2003.05583.x
M3 - Article
C2 - 14511002
AN - SCOPUS:0142120504
VL - 149
SP - 638
EP - 641
JO - British Journal of Dermatology
JF - British Journal of Dermatology
SN - 0007-0963
IS - 3
ER -